EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Fcγ receptor expression on monocytes and association with etanercept efficacy in rheumatoid arthritis: a prospective cohort study

Tongxin Wang, Hanchao Li, Li Zhu, Ying Pan, Jing Luo, Jing Zhang, Nan Hu, Lan He, Yining Sun

Frontiers in Pharmacology · 24.04.2026 · 17

DOI: 10.3389/fphar.2026.1807192 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Frontiers in Pharmacology, online erschienen am 24.04.2026. Verfasst von Tongxin Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To investigate whether Fcγ receptors (FcγRs) expression on peripheral blood monocytes predicts clinical response to etanercept in rheumatoid arthritis (RA).

Methods

In this prospective cohort study, FcγRs expression on peripheral blood monocyte subsets was analyzed by flow cytometry. The primary outcome was the change in DAS28-CRP from baseline to week 12. The secondary outcome was the change in DAS28-ESR.

Results

Following etanercept therapy, the proportion of FcγRI-positive monocytes and classical (CD14 ++ CD16 − ) monocytes was reduced, while the proportion of non-classical (CD14 + CD16 ++ ) monocytes was increased. Changes in intermediate monocytes (CD14 ++ CD16 + ) were positively correlated with both DAS28-CRP change and DAS28-ESR change at week 24 after etanercept therapy. Patients with high intermediate (CD14 ++ CD16 + ) monocytes showed significantly greater reductions in DAS28-CRP at week 12.

Conclusion

Intermediate monocytes (CD14 ++ CD16 + ) were correlated with improvements in DAS28-CRP achieved by week 12 following etanercept therapy. RA patients with low intermediate monocytes may derive less benefit from etanercept treatment.

Schlagwörter

Stichwörter der Autor:innen

DAS28-CRPDAS28-ESRFcγ receptorsetanerceptrheumatoid arthritis

Autor:innen und Institutionen

  • Department of Rheumatology and Immunology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.

Zitieren

APA

Wang, T., Li, H., Zhu, L., Pan, Y., Luo, J., Zhang, J., Hu, N., He, L., & Sun, Y. (2026). Fcγ receptor expression on monocytes and association with etanercept efficacy in rheumatoid arthritis: a prospective cohort study. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1807192

Vancouver

Wang T, Li H, Zhu L, Pan Y, Luo J, Zhang J, et al. Fcγ receptor expression on monocytes and association with etanercept efficacy in rheumatoid arthritis: a prospective cohort study. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1807192

BibTeX
@article{Wang2026,
  author = {Wang, Tongxin and Li, Hanchao and Zhu, Li and Pan, Ying and Luo, Jing and Zhang, Jing and Hu, Nan and He, Lan and Sun, Yining},
  title = {Fcγ receptor expression on monocytes and association with etanercept efficacy in rheumatoid arthritis: a prospective cohort study},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1807192}
}
Kostenlos starten →